Trials / Completed
CompletedNCT05799638
Strategy, Efficacy and Safety of Medication Usage in Heart Failure Patients Who Were Intolerable to GDMT
Medication Strategies in Heart Failure Patients Who Are Intolerable to Guideline-directed Medical Therapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 263 (actual)
- Sponsor
- Chongqing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
SEMI trial is a single-center, real-world based prospective cohort study. The study enrolled acute heart failure patients admitting to the hospital and intended to accept heart failure therapy. The current guideline recommend ACEI/ARB/ARNI, β blocker, SGLT2i and MRA as the cornerstone medication of HFrEF therapy, but a part patients were intolerable to GDMT because of hypotension, hyperkalemia or renal insufficency. Vericiguat is a new medication therapy choice for the patients with heart failure with reduced ejection fraction (HFrEF), it may has less influence on blood pressure, it is unkonwn about the efficacy and safety of vericiguat in patients who were intolerable to GDMT.
Detailed description
The study aim to provide evidence of medication strategy in heart failure patients, especially for patients who are intolerable for GDMT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Guideline-Directed Medication Treatment (GDMT) | GDMT contains ACEIs/ARBs/ARNI, β blockers, SGLT2is, MRAs. ACEI/ARB/ARNI and β blocker will gradually be titrated up to the maximum tolerable dose |
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2023-12-31
- Completion
- 2024-06-30
- First posted
- 2023-04-05
- Last updated
- 2024-08-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05799638. Inclusion in this directory is not an endorsement.